UroGen Pharma URGN Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $109.79M+21.4% | $90.4M+9.3% | $82.71M+28.5% | $64.36M+34.0% | ||
| -$153.49M-21.0% | -$126.87M-24.1% | -$102.24M+6.9% | -$109.78M+0.9% | ||
| -139.8%+0.5pp | -140.4%-16.7pp | -123.6%+47.0pp | -170.6%+60.1pp | ||
| $109.79M+21.4% | $90.4M+9.3% | $82.71M+28.5% | $64.36M+34.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is UroGen Pharma's revenue?
- UroGen Pharma (URGN) generated $140.5M in revenue over the trailing twelve months, up 52.9% year over year.
- Is UroGen Pharma profitable?
- UroGen Pharma is not currently profitable: it reported a net loss of $133.2M over the trailing twelve months, a -94.8% net margin.
- What are UroGen Pharma's profit margins?
- Gross margin is 89.7% and operating margin is -329.7%, with a -94.8% net margin.
- Where does UroGen Pharma's income statement data come from?
- Every line is extracted from UroGen Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
